Peter Schuld

566 total citations
15 papers, 201 citations indexed

About

Peter Schuld is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Peter Schuld has authored 15 papers receiving a total of 201 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 11 papers in Genetics and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Peter Schuld's work include Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Acute Lymphoblastic Leukemia research (4 papers). Peter Schuld is often cited by papers focused on Chronic Myeloid Leukemia Treatments (14 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Acute Lymphoblastic Leukemia research (4 papers). Peter Schuld collaborates with scholars based in Germany, Switzerland and France. Peter Schuld's co-authors include Mathiéu Molimard, Stéphane Bouchet, François‐Xavier Mahon, Karine Titier, Nicholas Moore, R. Lassalle, Coralie Bélanger, Thierry Buclin, Chantal Csajka and Nicolas Widmer and has published in prestigious journals such as Blood, Cancer and Haematologica.

In The Last Decade

Peter Schuld

11 papers receiving 199 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Schuld Germany 7 138 111 54 29 29 15 201
Eun‐Jung Jang South Korea 10 130 0.9× 109 1.0× 66 1.2× 16 0.6× 18 0.6× 26 202
Regina Cseuz United States 4 80 0.6× 59 0.5× 146 2.7× 21 0.7× 76 2.6× 8 233
Valentina Giai Italy 9 197 1.4× 132 1.2× 33 0.6× 127 4.4× 42 1.4× 24 287
Prasanna Kumar Nidamarthy India 6 86 0.6× 62 0.6× 10 0.2× 22 0.8× 11 0.4× 18 231
Satoshi Mano Japan 7 57 0.4× 76 0.7× 40 0.7× 37 1.3× 15 0.5× 15 242
A. Megan Cornelison United States 9 246 1.8× 144 1.3× 55 1.0× 92 3.2× 52 1.8× 16 324
Simone Claudiani United Kingdom 8 165 1.2× 136 1.2× 49 0.9× 19 0.7× 45 1.6× 31 209
Gioia Colafigli Italy 11 270 2.0× 178 1.6× 61 1.1× 99 3.4× 54 1.9× 41 333
Cristina Bucelli Italy 9 173 1.3× 162 1.5× 73 1.4× 81 2.8× 34 1.2× 33 250
Alex Allepuz Switzerland 6 100 0.7× 72 0.6× 36 0.7× 12 0.4× 18 0.6× 15 134

Countries citing papers authored by Peter Schuld

Since Specialization
Citations

This map shows the geographic impact of Peter Schuld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Schuld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Schuld more than expected).

Fields of papers citing papers by Peter Schuld

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Schuld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Schuld. The network helps show where Peter Schuld may publish in the future.

Co-authorship network of co-authors of Peter Schuld

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Schuld. A scholar is included among the top collaborators of Peter Schuld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Schuld. Peter Schuld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Lang, Fabian, Delphine Réa, Naoto Takahashi, et al.. (2025). Improving chronic myeloid leukemia management and quality of life: patient and physician survey on unmet needs from the CML SUN survey. Haematologica. 111(2). 597–608. 1 indexed citations
2.
Lang, Fabian, Delphine Réa, Naoto Takahashi, et al.. (2023). P668: CHRONIC MYELOID LEUKEMIA SURVEY ON UNMET NEEDS (CML SUN): BALANCING TOLERABILITY AND EFFICACY GOALS OF PATIENTS AND PHYSICIANS THROUGH SHARED TREATMENT DECISION-MAKING. HemaSphere. 7(S3). e8318962–e8318962. 1 indexed citations
3.
Schuld, Peter, et al.. (2023). CML-562 The Importance of Quality of Survivorship: US Results From the Chronic Myeloid Leukemia (CML) Survey on Unmet Needs (SUN). Clinical Lymphoma Myeloma & Leukemia. 23. S348–S348.
4.
5.
Hochhaus, Andreas, Susanne Saußele, François‐Xavier Mahon, et al.. (2023). PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE. HemaSphere. 7(S3). e5851092–e5851092. 1 indexed citations
6.
Schuld, Peter, Stephan Grzesiek, Judith Habazettl, et al.. (2020). Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP). Blood. 136(Supplement 1). 34–35. 8 indexed citations
7.
Schenk, Thomas, Jacqueline Maier, Georg‐Nikolaus Franke, et al.. (2019). Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor therapy (EUREKA registry). Journal of Cancer Research and Clinical Oncology. 145(6). 1645–1650. 8 indexed citations
8.
Gotta, Verena, Stéphane Bouchet, Nicolas Widmer, et al.. (2014). Large-scale imatinib dose–concentration–effect study in CML patients under routine care conditions. Leukemia Research. 38(7). 764–772. 41 indexed citations
9.
Bouchet, Stéphane, Karine Titier, Nicholas Moore, et al.. (2012). Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. Fundamental and Clinical Pharmacology. 27(6). 690–697. 55 indexed citations
10.
11.
12.
Mahon, François‐Xavier, Mathiéu Molimard, Andrea Davies, et al.. (2010). Imatinib Blood Level Testing – Current Perspectives and Key Questions. European Oncology & Haematology. 0(4). 59–59.
13.
Früehauf, Stefan, Julian Topaly, Eike C. Buss, et al.. (2007). Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 109(8). 1543–1549. 43 indexed citations
14.
15.
Dörr, Helmuth G., Siegfried Zabransky, B. Otten, et al.. (2003). Are Needle-Free Injections a Useful Alternative for Growth Hormone Therapy in Children? Safety and Pharmacokinetics of Growth Hormone Delivered by a New Needle-Free Injection Device Compared to a Fine Gauge Needle. Journal of Pediatric Endocrinology and Metabolism. 16(3). 383–92. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eun‐Jung Jang Breakdown of academic impact, for papers by Regina Cseuz Breakdown of academic impact, for papers by Valentina Giai Breakdown of academic impact, for papers by Prasanna Kumar Nidamarthy Breakdown of academic impact, for papers by Satoshi Mano Breakdown of academic impact, for papers by A. Megan Cornelison Breakdown of academic impact, for papers by Simone Claudiani Breakdown of academic impact, for papers by Gioia Colafigli Breakdown of academic impact, for papers by Cristina Bucelli Breakdown of academic impact, for papers by Alex Allepuz
Rankless by CCL
2026